For the Inventor, By the Inventor

Enter assignee name

Houston, TX, United States of America

Lasergen, Inc.

Calculating rank

USPTO Granted Patents = 14

EPO Patents = 2

Trademarks = 1

Forward Citations = 243

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

Michael L Metzker (14 out of 30 patents)

Brian P Stupi (14 out of 15 patents)

Weidong Wu (14 out of 18 patents)

4. Vladislav A Litosh (10 out of 10 patents)

5. Megan N Hersh (8 out of 9 patents)

6. Hong Li (4 out of 5 patents)

7. David Hertzog (4 out of 5 patents)

8. Sidney E Morris (4 out of 5 patents)

14 patents: Sort by Forward Citations

1. 10041115 - 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing (2018-08-07),

2. 9689035 - 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing (2017-06-27),

3. 9399798 - 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing (2016-07-26),

4. 9200319 - Nucleotides and nucleosides and methods for their use in DNA sequencing (2015-12-01),

5. 8969535 - Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing (2015-03-03),

6. 8889860 - 3'-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing (2014-11-18),

7. 8877905 - Nucleotides and nucleosides and methods for their use in DNA sequencing (2014-11-04),

8. 8497360 - Nucleotides and nucleosides and methods for their use in DNA sequencing (2013-07-30),

9. 8361727 - 3'OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing (2013-01-29),

10. 8198029 - 3'-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing (2012-06-12),

11. 8148503 - Nucleotides and nucleosides and methods for their use in DNA sequencing (2012-04-03),

12. 7964352 - 3'-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing (2011-06-21),

13. 7897737 - 3'-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing (2011-03-01),

14. 7893227 - 3'-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing (2011-02-22),

Company Overview

Lasergen, Inc. is a Houston-based company specializing in advanced laser technologies and solutions. The organization focuses on developing innovative systems for applications in various fields, including medical diagnostics and industrial manufacturing. With a commitment to enhancing precision and efficiency, Lasergen leverages its expertise in laser engineering to create cutting-edge products that meet the evolving needs of its clients. The company is dedicated to pushing the boundaries of technology while ensuring high standards of quality and performance.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

14 Patents

#366 in Houston, TX

#1,378 in Texas

#22,344 in US

#42,312 in the World

Houston, TX, United States of America

Lasergen, Inc.

Forward Citations = 243

8 inventors:

Michael L Metzker (14 out of 30 patents)

Brian P Stupi (14 out of 15 patents)

Weidong Wu (14 out of 18 patents)

4. Vladislav A Litosh (10 out of 10 patents)

5. Megan N Hersh (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lasergen, Inc.. Retrieved from https://idiyas.com/company/lasergen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…